These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Pipeline and key clinical candidates for these companies:
Axcella is “pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators,” or EMMs, the company states. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID, NASH, and the reduction in risk of OHE recurrence.
Telesis Bio says it is “empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges.” The Gibson Assembly method and the first commercial automated benchtop DNA and mRNA synthesis system enable rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets, the company has stated.
Recent news on these stocks:
November 13
Telesis Bio reported Q3 EPS (37c) against a consensus of (30c). Reported Q3 revenue $5.56M against a consensus of $7.4M. “This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our board of directors and management team,” said CEO Todd Nelson. Telesis Bio stated, “Based on current economic and product trends observed in its core markets, the company now believes that revenue for FY23 is estimated to be between $28M and $30M.”
Hear more from InvestingChannel by signing up for The Spill.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>